HK1123726A1 - Materials and methods for treating viral infections with a cysteamine compound - Google Patents

Materials and methods for treating viral infections with a cysteamine compound

Info

Publication number
HK1123726A1
HK1123726A1 HK09103170.7A HK09103170A HK1123726A1 HK 1123726 A1 HK1123726 A1 HK 1123726A1 HK 09103170 A HK09103170 A HK 09103170A HK 1123726 A1 HK1123726 A1 HK 1123726A1
Authority
HK
Hong Kong
Prior art keywords
materials
methods
viral infections
treating viral
cysteamine compound
Prior art date
Application number
HK09103170.7A
Other languages
English (en)
Inventor
Hao Yi Liang
Francis Chi
Qingfu Xu
Bill Piu Chan
Original Assignee
Omega Biopharma H K Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omega Biopharma H K Ltd filed Critical Omega Biopharma H K Ltd
Publication of HK1123726A1 publication Critical patent/HK1123726A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK09103170.7A 2005-11-28 2009-04-03 Materials and methods for treating viral infections with a cysteamine compound HK1123726A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74058405P 2005-11-28 2005-11-28
US81077306P 2006-06-02 2006-06-02
US81888506P 2006-07-06 2006-07-06
US84702006P 2006-09-25 2006-09-25
PCT/US2006/045652 WO2007062272A1 (fr) 2005-11-28 2006-11-28 Substances et methodes de traitement d'infections virales par un compose de cysteamine

Publications (1)

Publication Number Publication Date
HK1123726A1 true HK1123726A1 (en) 2009-06-26

Family

ID=37769370

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09103170.7A HK1123726A1 (en) 2005-11-28 2009-04-03 Materials and methods for treating viral infections with a cysteamine compound

Country Status (21)

Country Link
US (2) US8415398B2 (fr)
EP (1) EP1954258B8 (fr)
JP (1) JP5138603B2 (fr)
KR (1) KR101440629B1 (fr)
CN (1) CN102038667A (fr)
AP (1) AP2877A (fr)
AR (1) AR057623A1 (fr)
AU (1) AU2006318355B2 (fr)
BR (1) BRPI0619377A2 (fr)
CA (1) CA2631241C (fr)
DK (1) DK1954258T3 (fr)
ES (1) ES2392976T3 (fr)
HK (1) HK1123726A1 (fr)
IL (1) IL191705A (fr)
MX (1) MX2008006851A (fr)
MY (1) MY141003A (fr)
NZ (1) NZ568464A (fr)
PL (1) PL1954258T3 (fr)
PT (1) PT1954258E (fr)
TW (1) TWI401079B (fr)
WO (1) WO2007062272A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080226648A1 (en) * 2004-01-13 2008-09-18 Francis Chi Methods for Treating Stress and Affecting Biological Immune Systems
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
EA201600089A1 (ru) 2006-01-27 2017-01-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
US20100151042A1 (en) * 2007-05-25 2010-06-17 Hao Yi Liang Materials and Methods for Treating Influenza Infections
EP2276479B1 (fr) * 2008-04-15 2014-07-02 SineVir Therapeutics LLC Promédicaments d'inhibiteurs de la neuraminidase
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
WO2010138419A2 (fr) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Matières et procédés de traitement d'infections virales
US20120308608A1 (en) * 2010-02-01 2012-12-06 Megan Shaw Interferon-inducing compounds and uses thereof
EA025224B1 (ru) * 2010-04-15 2016-12-30 Байота Сайентифик Менеджмент Пти Лтд. ПРИМЕНЕНИЕ 3-ЭТОКСИ-6-{2-[1-(6-МЕТИЛПИРИДАЗИН-3-ИЛ)ПИПЕРИДИН-4-ИЛ]ЭТОКСИ}БЕНЗО[d]ИЗОКСАЗОЛА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ПРИ ЛЕЧЕНИИ ИЛИ ОБЛЕГЧЕНИИ СИМПТОМОВ АСТМЫ
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
AU2014318832B2 (en) 2013-09-12 2018-11-29 Janssen Biopharma, Inc. Aza-pyridone compounds and uses thereof
MX2017011655A (es) 2015-03-11 2018-04-30 Alios Biopharma Inc Compuestos de aza-piridona y usos de estos.
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
CA3017797A1 (fr) 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions servant a la liberation controlee de cysteamine et traitement systemique de troubles sensibles a la cysteamine
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US11758928B2 (en) 2016-12-15 2023-09-19 Société des Produits Nestlé S.A. Compositions and methods that modulate phosphorus or enzymes in a companion animal
EP3684418A4 (fr) 2017-09-20 2021-06-16 Thiogenesis Therapeutics, Inc. Méthodes de traitement des troubles sensibles à la cystéamine
US20230218571A1 (en) * 2020-04-01 2023-07-13 Thiogenesis Therapeutics, Inc. Cysteamine precursor compounds for the treatment of betacoronavirus infections
CA3176642A1 (fr) * 2020-05-13 2021-11-18 Regents Of The University Of Michigan Cysteamine pour le traitement d'une infection par sras-cov-2
WO2021240145A1 (fr) * 2020-05-25 2021-12-02 Novabiotics Limited Traitement anti-viral
WO2022040045A1 (fr) * 2020-08-18 2022-02-24 New Amsterdam Sciences, Inc. Mimétique de sod et procédés d'utilisation de celui-ci pour le traitement de la covid-19
WO2023107996A1 (fr) * 2021-12-07 2023-06-15 Cila Therapeutic Inc. Agents thérapeutiques antiviraux et leurs utilisations
WO2024009307A1 (fr) * 2022-07-06 2024-01-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Bloqueurs/inhibiteurs de viroporines en tant qu'agents anti-flavivirus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3538160A (en) 1965-03-24 1970-11-03 Smithkline Corp Pentacyclooctaneamines
US3483254A (en) 1967-01-03 1969-12-09 Merck & Co Inc 2-bornanemethylamines
US3496228A (en) 1967-02-16 1970-02-17 Smithkline Corp Aminotricyclononanes and the salts thereof
US3534084A (en) 1968-10-16 1970-10-13 Squibb & Sons Inc Adamantylamino-naphthyloxypropanols and related compounds
US3592934A (en) 1969-06-20 1971-07-13 Du Pont Pharmaceutical compositions and methods of controlling influenza a virus infection utilizing substituted adamantanes and tricyclo(4.3.1.13.8) undecanes
IT1055560B (it) 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5292773A (en) 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
ES2027527A6 (es) 1990-12-17 1992-06-01 Andromaco Lab Procedimiento para la obtencion de polimeros dotados de actividad antiviral.
DE4103177A1 (de) 1991-02-02 1992-08-06 Boehringer Mannheim Gmbh Thiazolo-(2,3-a)isoindol-derivate und diese enthaltende arzneimittel
US5314917A (en) 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
PT100914A (pt) 1991-09-30 1993-10-29 Jess G Thoene Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5725870A (en) 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
CA2173964A1 (fr) * 1993-10-15 1995-04-20 Jess G. Thoene Prevention de l'infection par le vih
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5684024A (en) 1996-01-25 1997-11-04 Viropharma Incorporated Pyrazole dimers compositions and methods for treating influenza
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
CA2326771A1 (fr) * 1998-03-30 1999-10-07 Endowment For Research In Human Biology, Inc. (The) Agents et procedes de modulation du transfert du zinc a l'aide de metallothioneine
DE19817511A1 (de) 1998-04-20 1999-10-21 Werner Slenczka Antivirale Wirksamkeit der Pantothensäure, des Dexpanthenols und ihrer Derivate. Hemmwirkung auf die Virusreplikation umhüllter Viren durch Blockade des Fusionsvorgangs.
US6063383A (en) 1999-01-28 2000-05-16 Hsu; Wu-Ching Pharmaceutical suppository composites for fever and influenza and method of producing the composites
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
RU2175230C1 (ru) 2001-01-23 2001-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с противовирусной активностью и способ ее получения
CA2445512C (fr) 2001-04-25 2010-10-12 Cobalz Limited Methode de traitement ou de prevention d'une carence fonctionnelle en vitamine b12 chez un individu, et compositions medicales utilisees dans cette methode
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US20060211748A1 (en) 2002-07-11 2006-09-21 Bain Allen I Sulphydryl compounds in combination with sulpha compounds
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003900064A0 (en) 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US20040191295A1 (en) 2003-03-28 2004-09-30 Locniskar Mary Frances Composition and method for viral inhibition
DE10340845A1 (de) * 2003-09-04 2005-03-31 Flavin-Koenig, Dana F., Dr. Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales

Also Published As

Publication number Publication date
KR101440629B1 (ko) 2014-09-15
MY141003A (en) 2010-02-12
CA2631241C (fr) 2014-02-11
TWI401079B (zh) 2013-07-11
NZ568464A (en) 2010-09-30
PL1954258T3 (pl) 2013-01-31
US9283198B2 (en) 2016-03-15
AP2877A (en) 2014-03-31
DK1954258T3 (da) 2012-10-15
IL191705A0 (en) 2009-02-11
BRPI0619377A2 (pt) 2011-09-27
IL191705A (en) 2013-11-28
PT1954258E (pt) 2012-10-22
CA2631241A1 (fr) 2007-05-31
JP5138603B2 (ja) 2013-02-06
EP1954258B8 (fr) 2012-10-10
AU2006318355B2 (en) 2012-01-12
AR057623A1 (es) 2007-12-05
US8415398B2 (en) 2013-04-09
EP1954258A1 (fr) 2008-08-13
AU2006318355A1 (en) 2007-05-31
WO2007062272A1 (fr) 2007-05-31
JP2009517395A (ja) 2009-04-30
US20070135525A1 (en) 2007-06-14
AP2008004511A0 (en) 2008-06-30
US20130338113A1 (en) 2013-12-19
KR20080077658A (ko) 2008-08-25
TW200733953A (en) 2007-09-16
EP1954258B1 (fr) 2012-09-05
CN102038667A (zh) 2011-05-04
MX2008006851A (es) 2008-10-09
ES2392976T3 (es) 2012-12-17

Similar Documents

Publication Publication Date Title
AP2877A (en) Materials and methods for treating viral infections with a cysteamine compound
AP2007004128A0 (en) Tricyclic-nucleoside compounds for treating viral infections
EP2034948A4 (fr) Composites renforces de fibres et procede pour leur fabrication
IL222922A (en) Antibodies against neurophilin-1 and their use
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
PL1961744T3 (pl) Związek zawierający grupę zasadową oraz jego zastosowanie
EP1899994A4 (fr) Materiaux composites faiblement magnetiques
SI1973950T1 (sl) Anti-EphB4 protitelesa in postopki njihove uporabe
GB2429966B (en) Shaft-ring gripper
GB0608938D0 (en) Particulate material
EP1841581A4 (fr) Composites et procedes de fabrication et d&#39;utilisation correspondants
ZA200805191B (en) Materials and methods for treating viral infections with a cysteamine compound
EP1921066A4 (fr) Composé de pyridylphénol et son utilisation
EP1862490A4 (fr) Compose carbodiimide et ses utilisations
HK1109939A1 (en) Techniques for handling lock-related inconsistencies
ZA200704988B (en) Particulate materials
EP1909789A4 (fr) Oxazolidinediones et thiazolidinediones antidiabetiques
EP1907381A4 (fr) Oxazolidinediones et thiazolidinediones antidiabétiques
GB2418909B (en) Material handling
GB2432359B (en) Closure
EP1904113A4 (fr) Composé neuroprotecteur efficace
IL186059A0 (en) Carbapenem derivatives and processes for the preparation thereof
GB0511532D0 (en) Particulate materials
GB0523637D0 (en) Process and compounds
GB0616902D0 (en) Closure

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181128